NEWS
CONFERENCES
MEDIA
PUBLICATIONS
CASE-BASED ROUNDTABLE
PARTNERS
RESOURCES
SUBSCRIBE

Your AI-Trained Oncology Knowledge Connection!

Opinion|Videos|October 25, 2023

Available First-Line Systemic Therapy Options for Patients With Metastatic Melanoma

Author(s)Hussein A. Tawbi, MD, PhD

Hussein Tawbi, MD, PhD, explains that for patients with melanoma without a BRAF mutation, first-line therapies primarily include immunotherapy-based (IO) checkpoint inhibitors, with PD-1 inhibitor combination therapies being the current standard of care.

Episodes in this series

Hussein Tawbi, MD, PhD, smiling at camera.

EP. 1 Case Presentation: A 78-Year-Old Man With Metastatic Melanoma

Hussein Tawbi, MD, PhD, smiling at camera.

EP. 2 Common Clinical Presentations of Metastatic Melanoma

Hussein Tawbi, MD, PhD, smiling at camera.

EP. 3 Significance of Biomarker and Genetic Testing in Diagnosing Metastatic Melanoma

Hussein Tawbi, MD, PhD, smiling at camera.

EP. 4 Available First-Line Systemic Therapy Options for Patients With Metastatic Melanoma

Hussein Tawbi, MD, PhD, smiling at camera.

EP. 5 The Role of Lymphocyte-Activation Gene 3 (LAG-3) in Metastatic Melanoma

Hussein Tawbi, MD, PhD, smiling at camera.

EP. 6 Relatlimab/Nivolumab in Metastatic Melanoma: Data From the RELATIVITY-047 Trial

Hussein Tawbi, MD, PhD, smiling at camera.

EP. 7 IO Monotherapy Versus Combination Dual IO Therapy for the First-Line Treatment of Metastatic Melanoma

Hussein Tawbi, MD, PhD, smiling at camera.

EP. 8 Key Trial Data in the Frontline Treatment of Metastatic Melanoma

Hussein Tawbi, MD, PhD, smiling at camera.

EP. 9 Managing Adverse Events in Patients With Metastatic Melanoma Receiving First-Line Systemic Therapy

Hussein Tawbi, MD, PhD, smiling at camera.

EP. 10 Case Presentation: A 67-Year-Old Woman With Stage IV Melanoma

Hussein Tawbi, MD, PhD, smiling at camera.

EP. 11 Available First-Line Systemic Therapy Options for Patients With Metastatic Melanoma with a BRAF Mutation

Hussein Tawbi, MD, PhD, smiling at camera.

EP. 12 Nivolumab/Ipilimumab Followed by Dabrafenib/Trametinib in Metastatic Melanoma: Data From the DREAMseq Trial

Hussein Tawbi, MD, PhD, smiling at camera.

EP. 13 Second-Line Treatment Options for Patients With Metastatic or Unresectable Melanoma After Disease Progression

Hussein Tawbi, MD, PhD, smiling at camera.

EP. 14 Clinical Pearls on the Treatment of Metastatic and Unresectable Melanoma

Newsletter

Stay up to date on practice-changing data in community practice.

Related Content

FDA Grants Orphan Drug Designation to IFx-2.0 for Advanced Melanoma

ByJonah Feldman

February 2nd 2026

Neoadjuvant Pembrolizumab Achieves High pCR Rates in Desmoplastic Melanoma

ByJonah Feldman

January 30th 2026

FDA Clears IND for Phase 3 Trial of iSCIB1+ in Advanced Melanoma

ByJonah Feldman

January 26th 2026

RFS Benefit Sustained at 5 Years for Intismeran Autogene in Melanoma

ByJonah Feldman

January 20th 2026

Walking Through the TIL Therapy Process in Advanced Melanoma

ByTargeted Oncology Staff

January 16th 2026

Latest CME

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

Marla D. Lipsyc-Sharf, MD; Ashley Frith, MD

The Inaugural Hawaii Breast Cancer: A Multidisciplinary Case-Based Conference

The Inaugural Hawaii Breast Cancer: A Multidisciplinary Case-Based Conference

Hope S. Rugo, MD, FASCO; Naoto T. Ueno, MD, PhD

43rd Annual Miami Breast Cancer Conference®

In-Person Event

43rd Annual Miami Breast Cancer Conference®

March 5-8, 2026

Medical Crossfire®: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2– Breast Cancer

Medical Crossfire®: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2– Breast Cancer

Joyce O’Shaughnessy, MD; William J. Gradishar, MD, FASCO, FACP; Heather McArthur, MD, MPH

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Patrick I. Borgen, MD; Joshua Feinberg, MD; Gary Schwartz, MD, FASA

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Rita Nanda, MD; William Gradishar, MD, FASCO, FACP; Komal Jhaveri, MD, FACP; Kevin Kalinsky, MD, MS

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Patrick I. Borgen, MD; E. Shelley Hwang, MD, MPH; Mark E. Robson, MD

Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care

Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care

Hope S. Rugo, MD, FASCO; Sara Hurvitz, MD, FACP; Jennifer Litton, MD, MHCM; Heather McArthur, MD, MPH

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Heather McArthur, MD, MPH; Komal Jhaveri, MD, FACP; Sara Tolaney, MD, MPH; Seth A. Wander, MD, PhD

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Joyce O’Shaughnessy, MD; William Gradishar, MD, FASCO, FACP; Heather McArthur, MD, MPH; Eleni Anastasia Tousimis, MD, MBA, FACS

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Reshma Jagsi, MD, DPhil; Kevin Kalinsky, MD, MS; Hope S. Rugo, MD, FASCO; Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Aditya Bardia, MD, MPH, FASCO; Joyce O’Shaughnessy, MD; Hope S. Rugo, MD; Paolo Tarantino, MD

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Grants Priority Review to Dato-DXd First-Line Metastatic TNBC

FDA Accepts NDA of Zanzalintinib Combo for Pretreated Metastatic CRC

Dr Shubham Pant Highlights Progress and Promise in Pancreatic Cancer Treatment

Gemogenovatucel-T Triples Overall Survival in High-Risk HRP Ovarian Cancer

New Phase 2 Study of Tri-Modal Immunotherapy for Indolent B-Cell Lymphoma Launches